![Tomas Navratil](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tomas Navratil
Corporate Officer/Principal bij
GLAUKOS CORPORATION
Vermogen: 9 M $ op 31-05-2026
Profiel
Dr. Tomas Navratil is a Chief Development Officer at Glaukos Corp.
He is on the Board of Directors at Severomoravske Vodovody a Kanalizace Ostrava as.
Dr. Navratil was previously employed as an Executive VP, Global Head-Research & Development by Nicox SA, a Senior Vice President-Development by Envisia Therapeutics, Inc., a Director-Medical & Scientific Affairs by Inspire Pharmaceuticals, Inc., a General Manager by Nicox Ophthalmics, Inc., and an Executive Director-Clinical Research by Parion Sciences, Inc. He received his undergraduate degree from The University of North Carolina at Charlotte and a doctorate degree from The University of North Carolina at Charlotte.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
GLAUKOS CORP 0,16% | 10-04-2026 | 90.370 ( 0,16% ) | 9 M $ | 31-05-2026 |
Actieve functies van Tomas Navratil
| Bedrijven | Functie | Begin |
|---|---|---|
| GLAUKOS CORPORATION | Corporate Officer/Principal | 01-04-2022 |
Severomoravske Vodovody a Kanalizace Ostrava as
 Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Engages in supply of drinking water and sewage services | Directeur/Bestuurslid | - |
Eerdere bekende functies van Tomas Navratil
| Bedrijven | Functie | Einde |
|---|---|---|
Nicox Ophthalmics, Inc.
 Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Corporate Officer/Principal | - |
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Hoofd Techniek/Wetenschap/O&O | - |
| NICOX SA | Hoofd Techniek/Wetenschap/O&O | - |
Parion Sciences, Inc.
 Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Corporate Officer/Principal | - |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Corporate Officer/Principal | - |
Opleiding van Tomas Navratil
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
19
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Health Technology |
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Commercial Services |
Glaukos Corp.
 Glaukos Corp. Medical SpecialtiesHealth Technology Operates as an ophthalmic medical device company | Health Technology |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Health Technology |
Nicox SA
 Nicox SA Pharmaceuticals: MajorHealth Technology Manufactures and sells ophthalmology biopharmaceuticals | Health Technology |
Severomoravske Vodovody a Kanalizace Ostrava as
Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Engages in supply of drinking water and sewage services | Utilities |
The University of North Carolina at Charlotte
 The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Health Technology |
